Invitation to iCMLf Forum for physicians attending ASH 2017
Each year The Max Foundation and the International CML Foundation come together during the American Society of Hematology (ASH) Meeting to host a forum for physicians treating chronic myeloid leukemia (CML) in low resource settings. The aim is to provide resources, share programmatic updates and enable robust discussions between leading CML experts and those treating the disease in low- and middle-income countries. This year’s forum will have a new component of small group discussions to allow for a more intimate question & answer session.
If you are a physician attending ASH this year, please join us at the iCMLf Forum for Physicians from Emerging Economic Regions, carried out in partnership with The Max Foundation, on Friday 8th December at 12.30pm. The iCMLf Forum is a unique experience to discuss and share experiences from all around the world. We hope to hear yours!
The 2017 Forum features ‘Perspectives on the Management of CML’ covering the topics of Molecular Monitoring for CML and Treatment Free Remission. Speakers include Dr. Susan Branford (Australia), Dr. Katia Pagnano (Brazil) and Dr. Susanne Saussele (Germany). This year, there is an expanded format for physicians from low- and middle-income countries to “Meet the Expert” at the end of the meeting. In the small group sessions, physicians will be able to hear from and chat with CML experts around the management of TKIs.
The iCMLf Forum for Physicians from Emerging Regions will be held:
12.30pm – 3:30 pm on Friday 8th December at the Doubletree Downtown Atlanta, Georgia, USA
If you are traveling to ASH this year, please consider joining this meeting. Feel free to share this email and the attached invitation with your colleagues. Please click here to reserve your place or for any queries please email melissa@cml-foundation.org.
The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.
Related Articles
New study confirms an excellent survival rate of cancer patients in a medication donation program
A new study led by Boston University School of Public Health, The Max Foundation, and Novartis Oncology found that chronic myeloid leukemia (CML) patients taking first-line treatment in low- and middle-income countries (LMICs) as part of the Glivec International Patient Assistance Program (GIPAP) have survival rates that compare favorably to those of CML patients receiving treatment in high-income countries.
Closing cancer care gaps in LMICs requires patient-centered systems
On the sidelines of UNGA80, global health leaders explored ways to expand access to care and build resilient health systems, and the critical role partnerships play in ensuring sustainable impact. Read More
Welcoming Two New Board Members: Dr. Mika Matsuzaki and Dr. Susan M. Jerian
Please join us in welcoming Mika Matsuzaki, PhD, and Susan M. Jerian, MD to The Max Foundation Board of Directors.
The Max Foundation uses cookies to improve your experience on our site. Please read our Privacy Policy for more information.
